Categories: News

United States Real-world Evidence (RWE) IT Solutions Market Report 2021: Transition to a Patient-centric Model is Moving Rapidly with Focus on Outcomes and Value

DUBLIN, March 10, 2021 /PRNewswire/ — The “United States Real-world Evidence (RWE) IT Solutions Market 2021 – Shifting Spotlight from Product- to Value-based Outcomes Intensifies Growth” report has been added to ResearchAndMarkets.com’s offering.

The US healthcare industry’s transition to a patient-centric model is moving rapidly with focus on outcomes and value; however, drug prices have increased and pharmaceutical research and development (R&D) productivity is at its lowest.

The healthcare industry and IT solutions providers are finding real-world evidence (RWE) as a potential solution to face these headwinds. The expansive data pools created by public-private efforts in combination with emerging technologies such as artificial intelligence (AI) and cloud capabilities is driving growth within the evidence-based medicine space.

In this report, the analyst’s Transformational Health team provides critical insights into the US RWE IT solutions market, highlighting the key growth opportunities, market revenue forecast, and trends that will play an important role in driving industry growth. RWE has become the focus for pharmaceutical and biotechnology companies, health technology assessment boards, the Food and Drug Administration (FDA), as well as payers and providers. Also covered in this study are technology trends, the competitive environment, and a capability benchmarking of select market participants.

Readers of this analysis, including IT solutions providers, private investors, academics, and government healthcare agencies, will find it useful to understand the status and revenue potential linked to the US RWE IT solutions market. This research service identifies the largest revenue-generating as well as the fastest-growing application and service segments in the US RWE industry. Furthermore, the impact of the COVID-19 pandemic on overall market revenue potential is discussed.

Finally, the analyst’s Transformational Health group offers a discussion of key growth opportunities that are centered on use of AI for clinical trial data management, utilization of cloud for improving commercial effectiveness, and connected digital products in clinical and post-market safety surveillance.

Overall, this study delivers insightful analysis of the RWE IT solutions ecosystem, a preview of the participants and competitive landscape, and the top growth opportunities – all elements essential to support stakeholders in their strategic decision journey.

Key Topics Covered:

1. Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?
  • The Strategic Imperative
  • The Impact of the Top Three Strategic Imperatives on the Real-world Evidence (RWE) IT Solutions Market
  • Growth Opportunities Fuel the Growth Pipeline Engine

2. Growth Opportunity Analysis, RWE IT Solutions Market

  • Real-world Evidence IT Solutions Scope of Analysis
  • Real-world Evidence Definitions
  • Real-world Evidence IT Solutions – Real-world Data *Sources
  • Real-world Evidence Applications and Impact
  • Real-world Evidence IT Solutions Market – Data and Analysis Flow
  • Real-world Evidence IT Solutions Market – Technology Trends
  • Real-world Evidence IT Solutions by Application Segment
  • Real-world Evidence IT Solutions by Service Segment
  • Key Competitors for Real-world Evidence IT Solutions
  • Key Growth Metrics for Real-world Evidence IT Solutions
  • Growth Drivers for Real-world Evidence IT Solutions
  • Growth Restraints for Real-world Evidence IT Solutions
  • Forecast Assumptions – Real-world Evidence IT Solutions
  • Revenue Forecast – Real-world Evidence IT Solutions
  • Revenue Forecast Analysis – Real-world Evidence IT Solutions
  • Revenue Forecast by Application Segment – Real-world Evidence IT Solutions
  • Revenue Forecast Analysis by Application Segment – Real-world Evidence IT Solutions
  • Revenue Forecast by Service Segment – Real-world Evidence IT Solutions
  • Revenue Forecast by Service Segment Analysis – Real-world Evidence IT Solutions
  • Competitive Environment – Real-world Evidence IT Solutions
  • Competitive Factors and Assessment – Real-world Evidence IT Solutions
  • Competitive Benchmarking – Real-world Evidence IT Solutions
  • Capability Mapping, Real-world Evidence IT Solutions
  • Competitive Benchmarking and Capability Mapping Analysis – Real-world Evidence IT Solutions
  • Revenue Share, Real-world Evidence IT Solutions
  • Revenue Share Analysis, Real-world Evidence IT Solutions

3. Growth Opportunity Universe, Real-world Evidence IT Solutions Market, US, 2020

  • Growth Opportunity Universe Summary, Real-world Evidence IT Solutions
  • Growth Opportunity 1 – AI for Supporting Clinical Trial RWD Management and Analysis, 2020
  • Growth Opportunity 2 – Cloud for RWE-supported Commercial Effectiveness, 2020
  • Growth Opportunity 3 – Digital Data Collection Tools for Clinical Trials and Post-market Safety Demonstration, 2020

4. Next Steps

For more information about this report visit https://www.researchandmarkets.com/r/7zaszl

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/united-states-real-world-evidence-rwe-it-solutions-market-report-2021-transition-to-a-patient-centric-model-is-moving-rapidly-with-focus-on-outcomes-and-value-301244878.html

SOURCE Research and Markets

Staff

Recent Posts

Zepp Health Introduces Zepp OS 4: Redefining Wearable Intelligence by Integrating OpenAI’s GPT-4o into its Amazfit Smartwatches

Amazfit Active becomes the world's first smartwatch under €200 to fully-integrate AI. MILPITAS, Calif., July…

1 hour ago

Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325

Investment will support investigation of Mission's small molecule drug MTX325 in patients with early-stage Parkinson's…

1 hour ago

Clarivate Identifies Six Breakthrough MedTech Trends in 2024 Set to Unlock New Industry Opportunities

New report highlights challenges and opportunities in resilient MedTech industry LONDON, July 2, 2024 /PRNewswire/…

1 hour ago

Poolbeg Pharma PLC Announces Change of Registered Address

Change of Registered AddressLONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg'…

4 hours ago

IRLAB’s Phase IIb Study of Pirepemat Can Proceed as Planned after Positive Opinion from External Safety Committee

GOTHENBURG, SWEDEN / ACCESSWIRE / July 2, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July…

4 hours ago